PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A

Cell Cycle

Volumn 11, Issue 23, 2012, Pages 4305-4309

  Patsoukis, Nikolaos ^a   Sari, Duygu ^a   Boussiotis, Vassiliki A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cdc25; Cdk2; PD 1; Smad3; T cells

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN CDC25A; PROTEIN P15; PROTEIN P27; PROTEIN TYROSINE PHOSPHATASE; RETINOBLASTOMA PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; CD4+ T LYMPHOCYTE; CELL CYCLE PROGRESSION; CYTOKINE PRODUCTION; DENDRITIC CELL; EFFECTOR CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; NATURAL KILLER T CELL; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION;

EID: 84870945643     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.22135     Document Type: Review

References (50)

1. Walker LS, Abbas AK. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol 2002; 2:11-9; PMID:11908514; http://dx.doi.org/10.1038/nri701.
2. Li L, Boussiotis VA. Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications. J Mol Med (Berl) 2006; 84:887-99; PMID:16972086; http://dx.doi.org/10.1007/s00109-006-0098-5.
3. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236:219-42; PMID:20636820; http://dx.doi.org/10. 1111/j.1600-065X.2010.00923.x.
4. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11:3887-95; PMID:1396582.
5. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677-704; PMID:18173375; http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331.
6. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003; 170:1257-66; PMID:12538684.
7. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2:261-8; PMID:11224527; http://dx.doi.org/10.1038/85330.
8. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001; 193:839-46; PMID:11283156; http://dx.doi.org/10.1084/jem.193.7. 839.
9. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5:1365-9; PMID:10581077; http://dx.doi.org/10.1038/70932.
10. Terawaki S, Chikuma S, Shibayama S, Hayashi T, Yoshida T, Okazaki T, et al. IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol 2011; 186:2772-9; PMID:21263073; http://dx.doi.org/10.4049/jimmunol.1003208.
11. Keir ME, Freeman GJ, Sharpe AH. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol 2007; 179:5064-70; PMID:17911591.
12. Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 2005; 6:280-6; PMID:15685176; http://dx.doi.org/10.1038/ni1165.
13. Reynoso ED, Elpek KG, Francisco L, Bronson R, Bellemare-Pelletier A, Sharpe AH, et al. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. J Immunol 2009; 182:2102-12; PMID:19201863; http://dx.doi.org/10.4049/jimmunol.0802769.
14. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006; 203:883-95; PMID:16606670; http://dx.doi.org/10.1084/jem.20051776.
15. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005; 54:307-14; PMID:15599732; http://dx.doi.org/10.1007/s00262-004-0593-x.
16. Currie AJ, Prosser A, McDonnell A, Cleaver AL, Robinson BW, Freeman GJ, et al. Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. J Immunol 2009; 183:7898-908; PMID:20007574; http://dx.doi.org/10.4049/jimmunol.0901060.
17. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 2009; 206:1327-37; PMID:19451266; http://dx.doi.org/10.1084/jem.20082173.
18. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009; 114:1545-52; PMID:19417208; http://dx.doi.org/10.1182/blood-2009-03-206672.
19. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12:1198-202; PMID:16917489; http://dx.doi.org/10.1038/nm1482.
20. Watanabe T, Bertoletti A, Tanoto TA. PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection. J Viral Hepat 2010; 17:453-8; PMID:20487259.
21. Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adams WC, et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006; 203:2281-92; PMID:16954372; http://dx.doi.org/10.1084/jem. 20061496.
22. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443:350-4; PMID:16921384; http://dx.doi.org/10.1038/nature05115.
23. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004; 18:2699-711; PMID:15545627; http://dx.doi.org/10.1101/ gad.1256504.
24. Russo AA, Jeffrey PD, Patten AK, Massagué J, Pavletich NP. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 1996; 382:325-31; PMID:8684460; http://dx.doi.org/10. 1038/382325a0.
25. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, et al. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 1999; 18:1571-83; PMID:10075928; http://dx.doi.org/10.1093/emboj/18.6.1571.
26. Boutros R, Dozier C, Ducommun B. The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol 2006; 18:185-91; PMID:16488126; http://dx.doi.org/10.1016/j.ceb.2006.02.003.
27. Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal 2012; 5:ra46; PMID:22740686; http://dx.doi.org/10.1126/scisignal.2002796.
28. Larrea MD, Wander SA, Slingerland JM. p27 as Jekyll and Hyde: regulation of cell cycle and cell motility. Cell Cycle 2009; 8:3455-61; PMID:19829074; http://dx.doi.org/10.4161/cc.8.21.9789.
29. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999; 98:859-69; PMID:10499802; http://dx.doi.org/10.1016/S0092-8674(00)81519-6.
30. Harbour JW, Dean DC. Chromatin remodeling and Rb activity. Curr Opin Cell Biol 2000; 12:685-9; PMID:11063932; http://dx.doi.org/10.1016/S0955-0674(00) 00152-6.
31. Hua XH, Newport J. Identification of a preinitiation step in DNA replication that is independent of origin recognition complex and cdc6, but dependent on cdk2. J Cell Biol 1998; 140:271-81; PMID:9442103; http://dx.doi.org/10.1083/jcb.140.2.271.
32. Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 2000; 14:2393-409; PMID:11018009; http://dx.doi.org/10. 1101/gad.813200.
33. Wells AD. Cyclin-dependent kinases: molecular switches controlling anergy and potential therapeutic targets for tolerance. Semin Immunol 2007; 19:173-9; PMID:17383195; http://dx.doi.org/10.1016/j.smim.2007.02.009.
34. Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 2004; 430:226-31; PMID:15241418; http://dx.doi.org/10.1038/nature02650.
35. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206:3015-29; PMID:20008522; http://dx.doi.org/10.1084/jem.20090847.
36. Massagué J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000; 1:169-78; PMID:11252892; http://dx.doi.org/10.1038/35043051.
37. Vigo E, Müller H, Prosperini E, Hateboer G, Cartwright P, Moroni MC, et al. CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. Mol Cell Biol 1999; 19:6379-95; PMID:10454584.
38. Iavarone A, Massagué J. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15. Nature 1997; 387:417-22; PMID:9163429; http://dx.doi.org/10.1038/387417a0.
39. Donzelli M, Squatrito M, Ganoth D, Hershko A, Pagano M, Draetta GF. Dual mode of degradation of Cdc25 A phosphatase. EMBO J 2002; 21:4875-84; PMID:12234927; http://dx.doi.org/10.1093/emboj/cdf491.
40. Donzelli M, Draetta GF. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep 2003; 4:671-7; PMID:12835754; http://dx.doi.org/10.1038/ sj.embor.embor887.
41. Donzelli M, Busino L, Chiesa M, Ganoth D, Hershko A, Draetta GF. Hierarchical order of phosphorylation events commits Cdc25A to betaTrCP-dependent degradation. Cell Cycle 2004; 3:469-71; PMID:14752276; http://dx.doi.org/10.4161/cc.3.4.770.
42. Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello NV, et al. Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 2003; 426:87-91; PMID:14603323; http://dx.doi.org/10.1038/ nature02082.
43. Jin J, Shirogane T, Xu L, Nalepa G, Qin J, Elledge SJ, et al. SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev 2003; 17:3062-74; PMID:14681206; http://dx.doi.org/10. 1101/gad.1157503.
44. Falck J, Mailand N, Syljuåsen RG, Bartek J, Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001; 410:842-7; PMID:11298456; http://dx.doi.org/10.1038/35071124.
45. Sørensen CS, Syljuåsen RG, Falck J, Schroeder T, Rönnstrand L, Khanna KK, et al. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 2003; 3:247-58; PMID:12676583; http://dx.doi.org/10.1016/S1535-6108(03)00048-5.
46. Hassepass I, Voit R, Hoffmann I. Phosphorylation at serine 75 is required for UV-mediated degradation of human Cdc25A phosphatase at the S-phase checkpoint. J Biol Chem 2003; 278:29824-9; PMID:12759351; http://dx.doi.org/10. 1074/jbc.M302704200.
47. Kittipatarin C, Li WQ, Bulavin DV, Durum SK, Khaled AR. Cell cycling through Cdc25A: transducer of cytokine proliferative signals. Cell Cycle 2006; 5:907-12; PMID:16628013; http://dx.doi.org/10.4161/cc.5.9.2693.
48. Ray D, Terao Y, Nimbalkar D, Chu LH, Donzelli M, Tsutsui T, et al. Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner. Mol Cell Biol 2005; 25:3338-47; PMID:15798217; http://dx.doi.org/10.1128/MCB.25.8.3338-3347.2005.
49. Khaled AR, Bulavin DV, Kittipatarin C, Li WQ, Alvarez M, Kim K, et al. Cytokine-driven cell cycling is mediated through Cdc25A. J Cell Biol 2005; 169:755-63; PMID:15928203; http://dx.doi.org/10.1083/jcb.200409099.
50. Macián F, García-Cózar F, Im SH, Horton HF, Byrne MC, Rao A. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 2002; 109:719-31; PMID:12086671; http://dx.doi.org/10.1016/S0092-8674(02)00767- 5.